From the Journals

Cardiovascular disease remains leading cause of type 2 diabetes mortality


 

FROM THE JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Cardiovascular disease was the leading cause of death among the over 16,000 patients with type 2 diabetes (T2DM) who were enrolled in the SAVOR-TIMI 53 trial.

Causes of death in patients with type 2 diabetes

Two-thirds (66.3%) of all 798 deaths after a median 2.1 years of follow-up were caused by one of five cardiovascular (CV) conditions, with sudden cardiac death accounting for the largest share (30.1%) of the total, Ilaria Cavallari, MD, PhD, and associates said in the Journal of the American College of Cardiology.

Most common among the non-CV causes was malignancy at 13.9% of all deaths in a T2DM population at high/very high risk for CV disease (n = 16,492), followed by infection (9.3%), the members of the TIMI Study Group noted.

After variables independently associated with overall mortality were identified, a subdistribution of competing risks was constructed using a competing-risk analysis based on the proportional hazards model, they explained.

Prior heart failure was the clinical variable most associated with CV death and could, along with older age, worse glycemic control, prior CV events, peripheral artery disease, and kidney complications, “identify a subgroup of T2DM patients at high risk of mortality who are likely to achieve the greatest benefit from aggressive management of modifiable risk factors and newer glucose-lowering agents,” the investigators wrote.

It was a pair of laboratory measurements, however, that had the largest subdistribution hazard ratios. “Interestingly, the magnitude of associations of abnormal N-terminal pro–B-type natriuretic peptide [sHR, 2.82] and high-sensitivity troponin T [sHR, 2.46] measured in a stable population were greater than clinical variables in the prediction of all causes of death,” Dr. Cavallari and associates said.

Recommended Reading

CVD deaths rose, imaging declined during pandemic
Journal of Clinical Outcomes Management
FDA alert confirms heart and cancer risks with tofacitinib (Xeljanz)
Journal of Clinical Outcomes Management
ColCORONA: More questions than answers for colchicine in COVID-19
Journal of Clinical Outcomes Management
New light cast on type 2 MI aims to sharpen diagnosis, therapy
Journal of Clinical Outcomes Management
Myocardial injury seen on MRI in 54% of recovered COVID-19 patients
Journal of Clinical Outcomes Management
Eating fish tied to fewer CVD events in high-risk people
Journal of Clinical Outcomes Management
Colchicine before PCI for acute MI fails to improve major outcomes
Journal of Clinical Outcomes Management
Ultraprocessed foods, many marketed as healthy, raise CVD risk
Journal of Clinical Outcomes Management
Arcalyst gets FDA nod as first therapy for recurrent pericarditis
Journal of Clinical Outcomes Management
Six pregnancy complications flag later heart disease risk
Journal of Clinical Outcomes Management